Article Information
History
- January 8, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Krishna Mohan Vadrevu, PhD1,
- Brunda Ganneru, PhD1,
- Siddharth Reddy, MSc1,
- Harsh Jogdand, DVM1,
- Dugyala Raju, PhD1,
- Usha Praturi, MSc1,
- Gajanan Sapkal, PhD2,
- Pragya Yadav, PhD2,
- Prabhakar Reddy, MD3,
- Savita Verma, MD4,
- Chandramani Singh, MD5,
- Sagar Vivek Redkar, MD6,
- Chandra Sekhar Gillurkar, MD7,
- Jitendra Singh Kushwaha, MD8,
- Satyajit Mohapatra, MD9,
- Amit Bhate, MD10,
- Sanjay Rai, MD11,
- Raches Ella, MBBS, MS12,*,
- Priya Abraham, PhD2,
- Sai Prasad, MBA1 and
- Krishna Ella, PhD1
- 1Bharat Biotech, Hyderabad, India
- 2Indian Council of Medical Research-National Institute of Virology, Pune, India
- 3Nizams Institute of Medical Sciences, Hyderabad, India
- 4Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, India
- 5All India Institute of Medical Sciences, Patna, India
- 6Redkar Hospital, Dargalim, India
- 7Gillurkar Hospital, Nagpur, India
- 8Prakhar Hospital, Kanpur, India
- 9SRM Hospital and Research Centre, Kattankulathur, India
- 10Jeevan Rekha Hospital, Belgaum, India
- 11All India Institute of Medical Sciences, New Delhi, India
- 12Independent Clinical Development Consultant, Cambridge, USA
- ↵*Corresponding author; email: rachesella{at}gmail.com
Posted January 08, 2022.
Persistence of immunity and impact of a third (booster) dose of an inactivated SARS-CoV-2 vaccine, BBV152; a phase 2, double-blind, randomised controlled trial
